TP53 and central nervous system cancer: After mEHT monotherapy, elevated tumor damage was also observed in 9L aggressive glioma, and MCF-7 (homozygous CDKN2Adel, heterozygous PIK3CA p.Glu545Lys, c.1633G > A; wild type TP53) hormone-sensitive breast cancer cell lines [42], as well as in Panc-1 (homozygous for TP53 gene mutation in c.818G > A, for CDKN2Adel; and heterozygous for KRAS c.35G > A [47]) pancreas ductal adenocarcinoma.